Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:193168.
doi: 10.1155/2012/193168. Epub 2012 Aug 1.

Chronic Condition Clusters and Polypharmacy among Adults

Affiliations

Chronic Condition Clusters and Polypharmacy among Adults

Ami Vyas et al. Int J Family Med. 2012.

Abstract

Objective. The primary objective of the study was to estimate the rates of polypharmacy among individuals with multimorbidity defined as chronic condition clusters and examine their associations with polypharmacy. Methods. Cross-sectional analysis of 10,528 individuals of age above 21, with at least one physical condition in cardiometabolic (diabetes or heart disease or hypertension), musculoskeletal (arthritis or osteoporosis), and respiratory (chronic obstructive pulmonary disease (COPD) or asthma) clusters from the 2009 Medical Expenditure Panel Survey. Chi-square tests and logistic regressions were performed to analyze the association between polypharmacy and multimorbidity. Results. Polypharmacy rates varied from a low of 7.2% among those with respiratory cluster to a high of 64.1% among those with all three disease clusters. Among those with two or more disease clusters, the rates varied from 28.3% for musculoskeletal and respiratory clusters to 41.8% for those with cardiometabolic and respiratory clusters. Individual with cardiometabolic conditions alone or in combination with other disease clusters were more likely to have polypharmacy. Compared to those with musculoskeletal and respiratory conditions, those with cardiometabolic and respiratory conditions had 1.68 times higher likelihood of polypharmacy. Conclusions. Rates of polypharmacy differed by specific disease clusters. Individuals with cardiometabolic condition were particularly at high risk of polypharmacy, suggesting greater surveillance for adverse drug interaction in this group.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what’s in a name? European Journal of General Practice. 1996;2:65–70.
    1. Fortin M, Soubhi H, Hudon C, Bayliss EA, Van den Akker M. Multimorbidity’s many challenges. British Medical Journal. 2007;334(7602):1016–1017. - PMC - PubMed
    1. Van den Akker M, Buntix F, Metsemakers JFM, Roos S, Knottnerus JA. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. Journal of Clinical Epidemiology. 1998;51(5):367–375. - PubMed
    1. Fortin M, Bravo G, Hudon C, Vanasse A, Lapointe L. Prevalence of multimorbidity among adults seen in family practice. Annals of Family Medicine. 2005;3(3):223–228. - PMC - PubMed
    1. Schneider KM, O’Donnell BE, Dean D. Prevalence of multiple chronic conditions in the United States’ Medicare population. Health and Quality of Life Outcomes. 2009;7, article 82 - PMC - PubMed

LinkOut - more resources